Rahul Gosain posted on LinkedIn:

“Amivantamab and Chemo now FDA approved in 2L mEGFR NSCLC after Osimertinib based off MARIPOSA2:

mOS 17.7mos with Amivantamab vs 15.3mos with chemo alone (HR 0.73), but ‘did NOT reach pre-specified significance’
mPFS2 16mos vs 11.6mos (HR: 0.64)
SKIPPirr: prophylaxis Dex to decrease infusion reactions when using Amivantamab.”

Drs. Rohit Gosain and Rahul Gosain (aka Oncology Brothers), are medical oncologists/hematologists. Through their social media platforms like X/Twitter, they actively engage with their audience. With their own YouTube channel and podcast, they provide accessible resources for cancer patients and their families.

Additionally, their participation in live conferences ensures that cancer patients receive the best care closer to home, reflecting their commitment to advancing oncology and improving patient outcomes through education and outreach.

Rahul Gosain: Amivantamab and Chemo now FDA approved in 2L mEGFR NSCLC after Osimertinib